Liposome–ligand conjugates: a review on the current state of art

References

• Hubbell JA, Chilkoti A. Chemistry. Nanomaterials for drug delivery. Science. 2012;337:303–305.
   PubMed Web of Science ®Google Scholar
• Ventola CL. The nanomedicine revolution: part 1: emerging concepts. P T. 2012;37:512–525.
   PubMedGoogle Scholar
• Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65:36–48.
   PubMed Web of Science ®Google Scholar
• Ozpolat B, Sood AK, Lopez-Berestein G. Liposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev. 2014;66:110–116.
   PubMed Web of Science ®Google Scholar
• He H, Lu Y, Qi J, et al. Adapting liposomes for oral drug delivery. Acta Pharm Sin B. 2019;9:36–48.
   PubMed Web of Science ®Google Scholar
• Uhumwangho MU, Okor RS. Current trends in the production and biomedical applications of liposomes: a review. J Med Biomed Res. 2005;2005:9–21.
   Google Scholar
• Laouini A, Jaafar-Maalej C, Limayem-Blouza I, et al. Preparation, characterization and applications of liposomes: state of the art. J Coll Sci Biotechnol. 2012;1:147–168.
   Google Scholar
• Bangham AD, Horne RW. Negative staining of phospholipids + their structural modification by-surface active agents as observed in electron microscope. J Mol Biol. 1964;8:660–668.
   PubMed Web of Science ®Google Scholar
• Bozzuto G, Molinari A. Liposomes as nanomedical devices. Int J Nanomed. 2015;10:975–999.
   PubMed Web of Science ®Google Scholar
• Sessa G, Weissmann G. Phospholipid spherules (liposomes) as a model for biological membranes. J Lip Res. 1968;9:310–310.
   PubMed Web of Science ®Google Scholar
• Fanciullino R, Ciccolini J. Liposome-encapsulated anticancer drugs: still waiting for the magic bullet? CMC. 2009;16:4361–4371.
   PubMed Web of Science ®Google Scholar
• Tanriverdi ST, Hilmioglu Polat S, Yesim Metin D, et al. Terbinafine hydrochloride loaded liposome film formulation for treatment of onychomycosis: in vitro and in vivo evaluation. J Lipos Res. 2016;26:163–173.
   PubMed Web of Science ®Google Scholar
• Eroglu I, Azizoglu E, Ozyazici M, et al. Effective topical delivery systems for corticosteroids: dermatological and histological evaluations. Drug Deliv. 2016;23:1502–1513.
   PubMed Web of Science ®Google Scholar
• Seleci M, Ag Seleci D, Scheper T, et al. Theranostic liposome-nanoparticle hybrids for drug delivery and bioimaging. Int J Mol Sci. 2017;18:E1415.
   PubMed Web of Science ®Google Scholar
• Carugo D, Bottaro E, Owen J, et al. Liposome production by microfluidics: potential and limiting factors. Sci Rep. 2016;6:25876.
   PubMed Web of Science ®Google Scholar
• Gregoriadis G. Liposomes in drug delivery: how it all happened. Pharmaceutics. 2016;8:19.
   PubMed Web of Science ®Google Scholar
• Gregoriadis G, Ryman BE. Lysosomal localization of fructofuranosidase-containing liposomes injected into rats. Biochem J. 1972;129:123–133.
   PubMed Web of Science ®Google Scholar
• Bulbake U, Doppalapudi S, Kommineni N, et al. Liposomal formulations in clinical use: an updated review. Pharmaceutics. 2017;9:12.
   PubMed Web of Science ®Google Scholar
• Singh RP, Gangadharappa HV, Mruthunjaya K. Phospholipids: unique carriers for drug delivery systems. J Drug Deliv Sci Technol. 2017;39:166–179.
   Web of Science ®Google Scholar
• Frezard F. Liposomes: from biophysics to the design of peptide vaccines. Braz J Med Biol Res. 1999;32:181–189.
   PubMed Web of Science ®Google Scholar
• Li J, Wang XL, Zhang T, et al. A review on phospholipids and their main applications in drug delivery systems. Asian J Pharm Sci. 2015;10:81–98.
   Web of Science ®Google Scholar
• Sharma A, Sharma US. Liposomes in drug delivery: progress and limitations. Int J Pharm. 1997;154:123–140.
   Web of Science ®Google Scholar
• van Hoogevest P. Review – an update on the use of oral phospholipid excipients. Eur J Pharm Sci. 2017;108:1–12.
   PubMed Web of Science ®Google Scholar
• Pollard D, Earnshaw WC, Lippincott-Schwartz J, et al. Membrane structure and dynamics In: Pollard D, Earnshaw WC, Lippincott-Schwartz J, et al. editors. Cell biology. Amsterdam (Netherlands): Elsevier Inc.; 2017. p. 227–239.
   Google Scholar
• Senior J, Gregoriadis G. Stability of small unilamellar liposomes in serum and clearance from the circulation – the effect of the phospholipid and cholesterol components. Life Sci. 1982;30:2123–2136.
   PubMed Web of Science ®Google Scholar
• Briuglia ML, Rotella C, McFarlane A, et al. Influence of cholesterol on liposome stability and on in vitro drug release. Drug Deliv Transl Res. 2015;5:231–242.
   PubMed Web of Science ®Google Scholar
• Shabbits JA, Chiu GNC, Mayer LD. Development of an in vitro drug release assay that accurately predicts in vivo drug retention for liposome-based delivery systems. J Control Release. 2002;84:161–170.
   PubMed Web of Science ®Google Scholar
• Yoshihara E, Nakae T. Cytolytic activity of liposomes containing stearylamine. Biochim Biophys Acta. 1986;854:93–101.
   PubMed Web of Science ®Google Scholar
• Boumann HA, Gubbens J, Koorengevel MC, et al. Depletion of phosphatidylcholine in yeast induces shortening and increased saturation of the lipid acyl chains: evidence for regulation of intrinsic membrane curvature in a eukaryote. MBoC. 2006;17:1006–1017.
   Google Scholar
• Krukemeyer MG, Krenn V, Huebner F, et al. History and possible uses of nanomedicine based on nanoparticles and nanotechnological progress. J Nanomed Nanotechnol. 2015;6:336–342.
   Google Scholar
• Rudokas M, Najlah M, Alhnan MA, et al. Liposome delivery systems for inhalation: a critical review highlighting formulation issues and anticancer applications. Med Princ Pract. 2016;25:60–72.
   PubMed Web of Science ®Google Scholar
• Akbarzadeh A, Rezaei-Sadabady R, Davaran S, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8:102.
   PubMed Web of Science ®Google Scholar
• Yingchoncharoen P, Kalinowski DS, Richardson DR. Lipid-based drug delivery systems in cancer therapy: what is available and what is yet to come. Pharmacol Rev. 2016;68:701–787.
   PubMed Web of Science ®Google Scholar
• Li M, Du C, Guo N, et al. Composition design and medical application of liposomes. Eur J Med Chem. 2019;164:640–653.
   PubMed Web of Science ®Google Scholar
• Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA. 1988;85:6949–6953.
   PubMed Web of Science ®Google Scholar
• Sercombe L, Veerati T, Moheimani F, et al. Advances and challenges of liposome assisted drug delivery. Front Pharmacol. 2015;6:286.
   PubMed Web of Science ®Google Scholar
• Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine. 2006;1:297–315.
   PubMed Web of Science ®Google Scholar
• Batzri S, Korn ED. Single bilayer liposomes prepared without sonication. Biochim Biophys Acta. 1973;298:1015–1019.
   PubMed Web of Science ®Google Scholar
• Allen TM, Hansen C, Rutledge J. Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial and other tissues. Biochim Biophys Acta. 1989;981:27–35.
   PubMed Web of Science ®Google Scholar
• Dhankhar R, Vyas SP, Jain AK, et al. Advances in novel drug delivery strategies for breast cancer therapy. Artif Cells Blood Substit Immobil Biotechnol. 2010;38:230–249.
   PubMed Web of Science ®Google Scholar
• Noble GT, Stefanick JF, Ashley JD, et al. Ligand-targeted liposome design: challenges and fundamental considerations. Trends Biotechnol. 2014;32:32–45.
   PubMed Web of Science ®Google Scholar
• Drummond DC, Meyer O, Hong K, et al. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev. 1999;51:691–743.
   PubMed Web of Science ®Google Scholar
• Mouritsen OG. Lipids, curvature, and nano-medicine. Eur J Lipid Sci Technol. 2011;113:1174–1187.
   PubMed Web of Science ®Google Scholar
• Northfelt DW, Dezube BJ, Thommes JA, et al. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi’s sarcoma after failure of standard chemotherapy. JCO. 1997;15:653–659.
   PubMed Web of Science ®Google Scholar
• Belfiore L, Saunders DN, Ranson M, et al. Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: challenges and opportunities. J Control Release. 2018;277:1–13.
   PubMed Web of Science ®Google Scholar
• Zangabad PS, Mirkiani S, Shahsavari S, et al. Stimulus-responsive liposomes as smart nanoplatforms for drug delivery applications. Nanotechnol Rev. 2018;7:95–122.
   PubMed Web of Science ®Google Scholar
• Yatvin MB, Weinstein JN, Dennis WH, et al. Design of liposomes for enhanced local release of drugs by hyperthermia. Science. 1978;202:1290–1293.
   PubMed Web of Science ®Google Scholar
• Ponce AM, Viglianti BL, Yu D, et al. Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects. J Natl Cancer Inst. 2007;99:53–63.
   PubMed Web of Science ®Google Scholar
• Hamzehzadeh L, Imanparast A, Tajbakhsh A, et al. New approaches to use nanoparticles for treatment of colorectal cancer; a brief review. Nanomed Res J. 2016;1:59–68.
   Google Scholar
• Needham D, Anyarambhatla G, Kong G, et al. A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res. 2000;60:1197–1201.
   PubMed Web of Science ®Google Scholar
• Cheng WY, Cheng H, Wan SS, et al. Dual-stimulus-responsive fluorescent supramolecular prodrug for antitumor drug delivery. Chem Mater. 2017;29:4218–4226.
   Web of Science ®Google Scholar
• Zhang WJ, Hong CY, Pan CY. Fabrication of reductive-responsive prodrug nanoparticles with superior structural stability by polymerization-induced self-assembly and functional nanoscopic platform for drug delivery. Biomacromolecules. 2016;17:2992–2999.
   PubMed Web of Science ®Google Scholar
• Liu X, Huang G. Formation strategies, mechanism of intracellular delivery and potential clinical applications of pH-sensitive liposomes. Asian J Pharm Sci. 2013;8:319–328.
   Google Scholar
• Ropert C, Lavignon M, Dubernet C, et al. Oligonucleotides encapsulated in pH sensitive liposomes are efficient toward Friend retrovirus. Biochem Biophys Res Commun. 1992;183:879–885.
   PubMed Web of Science ®Google Scholar
• Ding Y, Cui W, Sun D, et al. In vivo study of doxorubicin-loaded cell-penetrating peptide-modified pH-sensitive liposomes: biocompatibility, bio-distribution, and pharmacodynamics in BALB/c nude mice bearing human breast tumors. DDDT. 2017;11:3105–3117.
   PubMed Web of Science ®Google Scholar
• Zhang XM, Lin YX, Gillies RJ. Tumor pH and its measurement. J Nucl Med. 2010;51:1167–1170.
   PubMed Web of Science ®Google Scholar
• Yavlovich A, Viard M, Gupta K, et al. Low-visibility light-intensity laser-triggered release of entrapped calcein from 1,2-bis (tricosa-10,12-diynoyl)-sn-glycero-3-phosphocholine liposomes is mediated through a type I photoactivation pathway. Int J Nanomed. 2013;8:2575–2587.
   PubMed Web of Science ®Google Scholar
• Thompson DH, Gerasimov OV, Wheeler JJ, et al. Triggerable plasmalogen liposomes: improvement of system efficiency. Biochim Biophys Acta. 1996;1279:25–34.
   PubMed Web of Science ®Google Scholar
• Bibi S, Lattmann E, Mohammed AR, et al. Trigger release liposome systems: local and remote controlled delivery? J Microencapsul. 2012;29:262–276.
   PubMed Web of Science ®Google Scholar
• Jain A, Jain SK. Stimuli-responsive smart liposomes in cancer targeting. Curr Drug Targets. 2018;19:259–270.
   PubMed Web of Science ®Google Scholar
• Gogoi M, Kumar N, Patra S. Multifunctional magnetic liposomes for cancer imaging and therapeutic applications In: Holban AM, Grumezescu AM, editors. Nanoarchitectonics for smart delivery and drug targeting. Oxford (UK): William Andrew Applied Science Publishers; 2016. p. 743–782.
   Google Scholar
• Hermanson GT. Bioconjugate techniques. London: Academic Press; 2013.
   Google Scholar
• Marques-Gallego P, de Kroon AI. Ligation strategies for targeting liposomal nanocarriers. Biomed Res Int. 2014;2014:129458.
   PubMed Web of Science ®Google Scholar
• Loughrey HC, Wong KF, Choi LS, et al. Protein-liposome conjugates with defined size distributions. Biochim Biophys Acta. 1990;1028:73–81.
   PubMed Web of Science ®Google Scholar
• Nag OK, Awasthi V. Surface engineering of liposomes for stealth behavior. Pharmaceutics. 2013;5:542–569.
   PubMedGoogle Scholar
• Di Marco M, Shamsuddin S, Razak KA, et al. Overview of the main methods used to combine proteins with nanosystems: absorption, bioconjugation, and encapsulation. Int J Nanomed. 2010;5:37–49.
   PubMed Web of Science ®Google Scholar
• Shek PN, Heath TD. Immune response mediated by liposome-associated protein antigens. III. Immunogenicity of bovine serum albumin covalently coupled to vesicle surface. Immunology. 1983;50:101–106.
   PubMed Web of Science ®Google Scholar
• Mishra P, Nayak B, Dey RK. PEGylation in anti-cancer therapy: an overview. Asian J Pharm Sci. 2016;11:337–348.
   Web of Science ®Google Scholar
• Yin L, Su C, Ren TM, et al. MSAll strategy for comprehensive quantitative analysis of PEGylated-doxorubicin, PEG and doxorubicin by LC-high resolution q-q-TOF mass spectrometry coupled with all window acquisition of all fragment ion spectra. Analyst. 2017;142:4279–4288.
   PubMed Web of Science ®Google Scholar
• Riaz MK, Riaz MA, Zhang X, et al. Surface functionalization and targeting strategies of liposomes in solid tumor therapy: a review. IJMS. 2018;19:195.
   Google Scholar
• Gupta AS, von Recum A. Bioconjugation strategies: lipids, liposomes, polymersomes, and microbubbles. In: Narain R, editor. Chemistry of bioconjugates: synthesis, characterization, and biomedical applications. Hoboken (NJ): John Wiley & Sons, Inc.; 2014. p. 185.
   Google Scholar
• Ringsdorf H. Structure and properties of pharmacologically active polymers. J Polym Sci C Polym Symp. 1975;51:135–153.
   Google Scholar
• Martin FJ, Papahadjopoulos D. Irreversible coupling of immunoglobulin fragments to preformed vesicles. An improved method for liposome targeting. J Biol Chem. 1982;257:286–288.
   PubMed Web of Science ®Google Scholar
• Hutchinson FJ, Francis SE, Lyle IG, et al. The characterization of liposomes with covalently attached proteins. Biochim Biophys Acta. 1989;978:17–24.
   PubMed Web of Science ®Google Scholar
• Friedman AD, Claypool SE, Liu R. The smart targeting of nanoparticles. Curr Pharm Des. 2013;19:6315–6329.
   PubMed Web of Science ®Google Scholar
• Yu MK, Park J, Jon S. Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics. 2012;2:3–44.
   PubMed Web of Science ®Google Scholar
• Encapsula Nanosciences. Immunodox®-Succinyl (PEGylated). 2019 [cited 2019 Jun 9]. Available from: https://encapsula.com/products/liposomal-doxorubicin/surface-reactive-doxorubicin-liposomes-immunodox/amine-reactive-doxorubicin-liposomes/immunodox-succinyl-pegylated/
   Google Scholar
• Montalbetti C, Falque V. Amide bond formation and peptide coupling. Tetrahedron. 2005;61:10827–10852.
   Web of Science ®Google Scholar
• Marrazza G, Lucarelli F, Mascini M. Carbon electrodes in dna hybridisation research. Persp Bioanal. 2005;1:279–296.
   Google Scholar
• Werengowska-Ciecwierz K, Wisniewski M, Terzyk AP, et al. The chemistry of bioconjugation in nanoparticles-based drug delivery system. Adv Cond Matter Phys. 2015;2015. DOI:10.1155/2015/198175
   Web of Science ®Google Scholar
• Nakajima N, Ikada Y. Mechanism of amide formation by carbodiimide for bioconjugation in aqueous media. Bioconjug Chem. 1995;6:123–130.
   PubMed Web of Science ®Google Scholar
• Maruyama K, Takizawa T, Takahashi N, et al. Targeting efficiency of PEG-immunoliposome-conjugated antibodies at PEG terminals. Adv Drug Deliver Rev. 1997;24:235–242.
   Web of Science ®Google Scholar
• Kung VT, Redemann CT. Synthesis of carboxyacyl derivatives of phosphatidylethanolamine and use as an efficient method for conjugation of protein to liposomes. Biochim Biophys Acta. 1986;862:435–439.
   PubMedGoogle Scholar
• Mahesh S, Tang KC, Raj M. Amide bond activation of biological molecules. Molecules. 2018;23:2615.
   Web of Science ®Google Scholar
• Ansell SM, Harasym TO, Tardi PG, et al. Antibody conjugation methods for active targeting of liposomes. Methods Mol Med. 2000;25:51–68.
   PubMedGoogle Scholar
• Smyth DG, Konigsberg W, Blumenfeld OO. Reactions of N-ethylmaleimide with peptides and amino acids. Biochem J. 1964;91:589–589
   PubMed Web of Science ®Google Scholar
• Visser CC, Voorwinden LH, Harders LR, et al. Coupling of metal containing homing devices to liposomes via a maleimide linker: use of TCEP to stabilize thiol-groups without scavenging metals. J Drug Target. 2004;12:569–573.
   PubMed Web of Science ®Google Scholar
• Schelte P, Boeckler C, Frisch B, et al. Differential reactivity of maleimide and bromoacetyl functions with thiols: application to the preparation of liposomal diepitope constructs. Bioconjugate Chem. 2000;11:118–123.
   PubMed Web of Science ®Google Scholar
• Shahinian S, Silvius JR. A novel strategy affords high-yield coupling of antibody Fab' fragments to liposomes. Biochim Biophys Acta. 1995;1239:157–167.
   PubMed Web of Science ®Google Scholar
• Winther JR, Thorpe C. Quantification of thiols and disulfides. Biochim Biophys Acta. 2014;1840:838–846.
   PubMed Web of Science ®Google Scholar
• Chandrasekhar S, Epling DE, Sophocleous AM, et al. Thiol-disulfide exchange in peptides derived from human growth hormone. J Pharm Sci. 2014;103:1032–1042.
   PubMed Web of Science ®Google Scholar
• Shaik MS, Kanikkannan N, Singh M. Conjugation of anti-My9 antibody to stealth monensin liposomes and the effect of conjugated liposomes on the cytotoxicity of immunotoxin. J Control Release. 2001;76:285–295.
   PubMed Web of Science ®Google Scholar
• Kolmel DK, Kool ET. Oximes and hydrazones in bioconjugation: mechanism and catalysis. Chem Rev. 2017;117:10358–10376.
   PubMed Web of Science ®Google Scholar
• Zhong XB, Reynolds R, Kidd JR, et al. Single-nucleotide polymorphism genotyping on optical thin-film biosensor chips. Proc Natl Acad Sci USA. 2003;100:11559–11564.
   PubMed Web of Science ®Google Scholar
• Kozlov IA, Melnyk PC, Stromsborg KE, et al. Efficient strategies for the conjugation of oligonucleotides to antibodies enabling highly sensitive protein detection. Biopolymers. 2004;73:621–630.
   PubMed Web of Science ®Google Scholar
• Gershoni JM, Bayer EA, Wilchek M. Blot analyses of glycoconjugates: enzyme-hydrazide – a novel reagent for the detection of aldehydes. Anal Biochem. 1985;146:59–63.
   PubMed Web of Science ®Google Scholar
• Bayer EA, Safars M, Wilchek M. Selective labeling of sulfhydryls and disulfides on blot transfers using avidin-biotin technology: studies on purified proteins and erythrocyte membranes. Anal Biochem. 1987;161:262–271.
   PubMed Web of Science ®Google Scholar
• Harding JA, Engbers CM, Newman MS, et al. Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes. Biochim Biophys Acta. 1997;1327:181–192.
   PubMed Web of Science ®Google Scholar
• Chua MM, Fan ST, Karush F. Attachment of immunoglobulin to liposomal membrane via protein carbohydrate. Biochim Biophys Acta. 1984;800:291–300.
   PubMedGoogle Scholar
• Irby D, Du CG, Li F. Lipid-drug conjugate for enhancing drug delivery. Mol Pharm. 2017;14:1325–1338.
   PubMed Web of Science ®Google Scholar
• Xiong MP, Yanez JA, Remsberg CM, et al. Formulation of a geldanamycin prodrug in mPEG-b-PCL micelles greatly enhances tolerability and pharmacokinetics in rats. J Control Release. 2008;129:33–40.
   PubMed Web of Science ®Google Scholar
• Perkins WR, Ahmad I, Li XG, et al. Novel therapeutic nano-particles (lipocores): trapping poorly water soluble compounds. Int J Pharm. 2000;200:27–39.
   PubMed Web of Science ®Google Scholar
• Guo X, Szoka FC. Steric stabilization of fusogenic liposomes by a low-pH sensitive PEG-diortho ester-lipid conjugate. Bioconjugate Chem. 2001;12:291–300.
   PubMed Web of Science ®Google Scholar
• Livnah O, Bayer EA, Wilchek M, et al. Three-dimensional structures of avidin and the avidin-biotin complex. Proc Natl Acad Sci USA. 1993;90:5076–5080.
   PubMed Web of Science ®Google Scholar
• Bratthauer GL. The avidin-biotin complex (ABC) method and other avidin-biotin binding methods. Methods Mol Biol. 2010;588:257–270.
   PubMedGoogle Scholar
• Koo H, Lee S, Na JH, et al. Bioorthogonal copper-free click chemistry in vivo for tumor-targeted delivery of nanoparticles. Angew Chem Int Ed. 2012;51:11836–11840.
   PubMed Web of Science ®Google Scholar
• Sun Q, Kang Z, Xue L, et al. A collaborative assembly strategy for tumor-targeted siRNA delivery. J Am Chem Soc. 2015;137:6000–6010.
   PubMed Web of Science ®Google Scholar
• Lombardo D, Calandra P, Barreca D, et al. Soft interaction in liposome nanocarriers for therapeutic drug delivery. Nanomaterials (Basel). 2016;6:125.
   Google Scholar
• Aharon D, Weitman H, Ehrenberg B. The effect of liposomes’ surface electric potential on the uptake of hematoporphyrin. Biochim Biophys Acta. 2011;1808:2031–2035.
   PubMed Web of Science ®Google Scholar
• Adhikari P, Pal P, Das AK, et al. Nano lipid-drug conjugate: an integrated review. Int J Pharm. 2017;529:629–641.
   PubMed Web of Science ®Google Scholar
• Manjappa AS, Chaudhari KR, Venkataraju MP, et al. Antibody derivatization and conjugation strategies: application in preparation of stealth immunoliposome to target chemotherapeutics to tumor. J Control Release. 2011;150:2–22.
   PubMed Web of Science ®Google Scholar
• Neupane YR, Sabir MD, Ahmad N, et al. Lipid drug conjugate nanoparticle as a novel lipid nanocarrier for the oral delivery of decitabine: ex vivo gut permeation studies. Nanotechnology. 2013;24:415102.
   PubMed Web of Science ®Google Scholar
• Stuhne-Sekalec L, Stanacev NZ. Liposomes as cyclosporin A carriers: the influence of ordering of hydrocarbon chains of phosphatidylglycerol liposomes on the association with and topography of cyclosporin A. J Microencapsul. 1991;8:283–294.
   PubMed Web of Science ®Google Scholar
• Maruyama K, Ishida O, Takizawa T, et al. Possibility of active targeting to tumor tissues with liposomes. Adv Drug Deliv Rev. 1999;40:89–102.
   PubMed Web of Science ®Google Scholar
• Leserman LD, Machy P, Barbnet J. Covalent coupling of monoclonal antibodies and protein A to liposomes: specific interaction with cells in vitro and in vivo. In: Gregoriadis G, editor. Liposome technology. Vol.2. Boca Raton (FL): Taylor and Francis; 2018. p. 29–40.
   Google Scholar
• Feng L, Mumper RJ. A critical review of lipid-based nanoparticles for taxane delivery. Cancer Lett. 2013;334:157–175.
   PubMed Web of Science ®Google Scholar
• Palmer JL. Nisonoff A. Reduction and reoxidation of a critical disulfide bond in rabbit antibody molecule. J Biol Chem. 1963;238:2393.
   Web of Science ®Google Scholar
• Sun MMC, Beam KS, Cerveny CG, et al. Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconjugate Chem. 2005;16:1282–1290.
   PubMed Web of Science ®Google Scholar
• Raso V, Lawrence J. Carboxylic ionophores enhance the cytotoxic potency of ligand- and antibody-delivered ricin A chain. J Exp Med. 1984;160:1234–1240.
   PubMed Web of Science ®Google Scholar
• Griffin T, Raso V. Monensin in lipid emulsion for the potentiation of ricin A chain immunotoxins. Cancer Res. 1991;51:4316–4322.
   PubMed Web of Science ®Google Scholar
• Demidenko ZN, Zubova SG, Bukreeva EI, et al. Rapamycin decelerates cellular senescence. Cell Cycle. 2009;8:1888–1895.
   PubMed Web of Science ®Google Scholar
• Demidenko ZN, Shtutman M, Blagosklonny MV. Pharmacologic inhibition of MEK and PI-3K converges on the mTOR/S6 pathway to decelerate cellular senescence. Cell Cycle. 2009;8:1896–1900.
   PubMed Web of Science ®Google Scholar
• Demidenko ZN, Blagosklonny MV. Growth stimulation leads to cellular senescence when the cell cycle is blocked. Cell Cycle. 2008;7:3355–3361.
   PubMed Web of Science ®Google Scholar
• Nguyen HT, Thapa RK, Shin BS, et al. CD9 monoclonal antibody-conjugated PEGylated liposomes for targeted delivery of rapamycin in the treatment of cellular senescence. Nanotechnology. 2017;28:095101.
   PubMed Web of Science ®Google Scholar
• Heath WR, Carbone FR. Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol. 2001;19:47–64.
   PubMed Web of Science ®Google Scholar
• Allison AC, Gregoriadis G. Liposomes as immunological adjuvants. Nature. 1974;252:252–252.
   PubMed Web of Science ®Google Scholar
• Alving CR. Liposomes as carriers of vaccines. In: Talwar GP, editor. Progress in vaccinology. Vol. 2. New York: Springer; 1989. p. 429–437.
   Google Scholar
• Tanaka Y, Taneichi M, Kasai M, et al. Liposome-coupled antigens are internalized by antigen-presenting cells via pinocytosis and cross-presented to CD8 T cells. PLoS One. 2010;5:e15225.
   PubMed Web of Science ®Google Scholar
• Taneichi M, Ishida H, Kajino K, et al. Antigen chemically coupled to the surface of liposomes are cross-presented to CD8+ T cells and induce potent antitumor immunity. J Immunol. 2006;177:2324–2330.
   PubMed Web of Science ®Google Scholar
• Dissanayake S, Denny WA, Gamage S, et al. Recent developments in anticancer drug delivery using cell penetrating and tumor targeting peptides. J Control Release. 2017;250:62–76.
   PubMed Web of Science ®Google Scholar
• Silva S, Almeida AJ, Vale N. Combination of cell-penetrating peptides with nanoparticles for therapeutic application: a review. Biomolecules. 2019;9:22.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang L, Hu Y, et al. Cell-permeable NF-kappaB inhibitor-conjugated liposomes for treatment of glioma. J Control Release. 2018;289:102–113.
   PubMed Web of Science ®Google Scholar
• Kang MH, Park MJ, Yoo HJ, et al. RIPL peptide (IPLVVPLRRRRRRRRC)-conjugated liposomes for enhanced intracellular drug delivery to hepsin-expressing cancer cells. Eur J Pharm Biopharm. 2014;87:489–499.
   PubMed Web of Science ®Google Scholar
• Kwon SS, Kim SY, Kong BJ, et al. Cell penetrating peptide conjugated liposomes as transdermal delivery system of Polygonum aviculare L. extract. Int J Pharm. 2015;483:26–37.
   PubMed Web of Science ®Google Scholar
• Cobb M. Oswald Avery, DNA, and the transformation of biology. Curr Biol. 2014;24:R55–60.
   PubMed Web of Science ®Google Scholar
• Jones MR, Seeman NC, Mirkin CA. Nanomaterials. Programmable materials and the nature of the DNA bond. Science. 2015;347:1260901.
   PubMed Web of Science ®Google Scholar
• Pinheiro AV, Han D, Shih WM, et al. Challenges and opportunities for structural DNA nanotechnology. Nat Nanotechnol. 2011;6:763–772.
   PubMed Web of Science ®Google Scholar
• Alberts B, Lewis J, Raff M, et al. Molecular biology of the cell. New York (NY): Garland Science; 2002.
   Google Scholar
• Wonder E, Simon-Gracia L, Scodeller P, et al. Competition of charge-mediated and specific binding by peptide-tagged cationic liposome-DNA nanoparticles in vitro and in vivo. Biomaterials. 2018;166:52–63.
   PubMed Web of Science ®Google Scholar
• Lopez A, Liu J. DNA oligonucleotide-functionalized liposomes: bioconjugate chemistry, biointerfaces, and applications. Langmuir. 2018;34:15000–15013.
   PubMed Web of Science ®Google Scholar
• Laursen MB, Pakula MM, Gao S, et al. Utilization of unlocked nucleic acid (UNA) to enhance siRNA performance in vitro and in vivo. Mol Biosyst. 2010;6:862–870.
   PubMed Web of Science ®Google Scholar
• Liu J, Cao Z, Lu Y. Functional nucleic acid sensors. Chem Rev. 2009;109:1948–1998.
   PubMed Web of Science ®Google Scholar
• van der Meulen SA, Dubacheva GV, Dogterom M, et al. Quartz crystal microbalance with dissipation monitoring and spectroscopic ellipsometry measurements of the phospholipid bilayer anchoring stability and kinetics of hydrophobically modified DNA oligonucleotides. Langmuir. 2014;30:6525–6533.
   PubMed Web of Science ®Google Scholar
• Jakobsen U, Simonsen AC, Vogel S. DNA controlled assembly of soft nanoparticles. Nucleic Acids Symp Ser. 2008; 52:225–226.
   Google Scholar
• Cogoi S, Jakobsen U, Pedersen EB, et al. Lipid-modified G4-decoy oligonucleotide anchored to nanoparticles: delivery and bioactivity in pancreatic cancer cells. Sci Rep. 2016;6:38468.
   PubMed Web of Science ®Google Scholar
• Meckes B, Banga RJ, Nguyen ST, et al. Enhancing the stability and immunomodulatory activity of liposomal spherical nucleic acids through lipid-tail DNA modifications. Small. 2018;14:1702909.
   Web of Science ®Google Scholar
• Deng L, Zhang Y, Ma L, et al. Comparison of anti-EGFR-Fab' conjugated immunoliposomes modified with two different conjugation linkers for siRNa delivery in SMMC-7721 cells. Int J Nanomed. 2013;8:3271–3283.
   PubMed Web of Science ®Google Scholar
• Lundin KE, Gissberg O, Smith CI. Oligonucleotide therapies: the past and the present. Hum Gene Ther. 2015;26:475–485.
   PubMed Web of Science ®Google Scholar
• Yang L, Zhang X, Ye M, et al. Aptamer-conjugated nanomaterials and their applications. Adv Drug Deliv Rev. 2011;63:1361–1370.
   PubMed Web of Science ®Google Scholar
• Wilson DS, Szostak JW. In vitro selection of functional nucleic acids. Annu Rev Biochem. 1999;68:611–647.
   PubMed Web of Science ®Google Scholar
• Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature. 1990;346:818–822.
   PubMed Web of Science ®Google Scholar
• Yang X, Li N, Gorenstein DG. Strategies for the discovery of therapeutic aptamers. Expert Opin Drug Discov. 2011;6:75–87.
   PubMed Web of Science ®Google Scholar
• Dong J, Cao Y, Shen H, et al. EGFR aptamer-conjugated liposome-polycation-DNA complex for targeted delivery of SATB1 small interfering RNA to choriocarcinoma cells. Biomed Pharmacother. 2018;107:849–859.
   PubMed Web of Science ®Google Scholar
• Tarentino AL, Phelan AW, Plummer TH. Jr. 2-Iminothiolane: a reagent for the introduction of sulphydryl groups into oligosaccharides derived from asparagine-linked glycans. Glycobiology. 1993;3:279–285.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chan JW, Moretti A, et al. Designing polymers with sugar-based advantages for bioactive delivery applications. J Control Release. 2015;219:355–368.
   PubMed Web of Science ®Google Scholar
• Plotz PH, Rifai A. Stable, soluble, model immune complexes made with a versatile multivalent affinity-labeling antigen. Biochemistry. 1982;21:301–308.
   PubMed Web of Science ®Google Scholar
• Yeh HW, Lin TS, Wang HW, et al. S-Linked sialyloligosaccharides bearing liposomes and micelles as influenza virus inhibitors. Org Biomol Chem. 2015;13:11518–11528.
   PubMed Web of Science ®Google Scholar
• Wang Q, Chao YM. Multifunctional quantum dots and liposome complexes in drug delivery. J Biomed Res. 2018;32:91–106.
   PubMed Web of Science ®Google Scholar
• Alivisatos AP. Perspectives on the physical chemistry of semiconductor nanocrystals. J Phys Chem. 1996;100:13226–13239.
   Web of Science ®Google Scholar
• Pickett NL, O?Brien P. Syntheses of semiconductor nanoparticles using single-molecular precursors. Chem Record. 2001;1:467–479.
   PubMed Web of Science ®Google Scholar
• Bangal M, Ashtaputre S, Marathe S, et al. Semiconductor nanoparticles. Hyperfine Interact. 2005;160:81–94.
   Google Scholar
• Ekimov AI, Onushchenko AA. Quantum size effect in three-dimensional microscopic semiconductor crystals. J Exp Theor Phys Lett. 1981;34:345–349.
   Google Scholar
• Ekimov AI, Onushchenko AA. Quantum size effect in the optical-spectra of semiconductor micro-crystals. Sov Phys Semicond. 1982;16:775–778.
   Web of Science ®Google Scholar
• Efros AIL. Interband absorption of light in a semiconductor sphere. Sov Phys Semicond. 1982;16:772–775.
   Web of Science ®Google Scholar
• Efros AIL, Kharchenko VA, Rosen M. Breaking the phonnon bottleneck in nanometer quantum dots: role of Auger-like process. Solid State Commun. 1995;93:281–284.
   Web of Science ®Google Scholar
• Brus LE. A simple model for the ionization potential, electron affinity, and aqueous redox potentials of small semiconductor crystallites. J Chem Phys. 1983;79:5566–5571.
   Web of Science ®Google Scholar
• Weng KC, Noble CO, Papahadjopoulos-Sternberg B, et al. Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo. Nano Lett. 2008;8:2851–2857.
   PubMed Web of Science ®Google Scholar
• Karamanou M, Papaioannou TG, Stefanadis C, et al. Genesis of ultrasonic microbubbles: a quick historical overview. CPD. 2012;18:2115–2117.
   Google Scholar
• Sirsi S, Borden M. Microbubble compositions, properties and biomedical applications. Bubble Sci Eng Technol. 2009;1:3–17.
   PubMedGoogle Scholar
• Lindner JR, Song J, Jayaweera AR, et al. Microvascular rheology of definity microbubbles after intra-arterial and intravenous administration. J Am Soc Echocardiogr. 2002;15:396–403.
   PubMed Web of Science ®Google Scholar
• Lentacker I, De Geest BG, Vandenbroucke RE, et al. Ultrasound-responsive polymer-coated microbubbles that bind and protect DNA. Langmuir. 2006;22:7273–7278.
   PubMed Web of Science ®Google Scholar
• Malik R, Pancholi K, Melzer A. Microbubble-liposome conjugate: payload evaluation of potential theranostic vehicle. Nanobiomedicine. 2016;3:1849543516670806.
   Google Scholar
• Chen CC, Borden MA. Ligand conjugation to bimodal poly(ethylene glycol) brush layers on microbubbles. Langmuir. 2010;26:13183–13194.
   PubMed Web of Science ®Google Scholar
• Zhitomirsky B, Assaraf YG. Lysosomal accumulation of anticancer drugs triggers lysosomal exocytosis. Oncotarget. 2017;8:45117–45132.
   PubMedGoogle Scholar
• Veronese FM, Morpurgo M. Bioconjugation in pharmaceutical chemistry. Farmaco. 1999;54:497–516.
   PubMedGoogle Scholar
• Baek SE, Lee KH, Park YS, et al. RNA aptamer-conjugated liposome as an efficient anticancer drug delivery vehicle targeting cancer cells in vivo. J Control Release. 2014;196:234–242.
   PubMed Web of Science ®Google Scholar
• Boussios S, Pentheroudakis G, Katsanos K, et al. Systemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and management. Ann Gastroenterol. 2012;25:106–118.
   PubMedGoogle Scholar
• Tiwari G, Tiwari R, Sriwastawa B, et al. Drug delivery systems: an updated review. Int J Pharm Investig. 2012;2:2–11.
   PubMedGoogle Scholar
• Mao Y, Triantafillou G, Hertlein E, et al. Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies. Clin Cancer Res. 2013;19:347–356.
   PubMed Web of Science ®Google Scholar
• Li SD, Huang L. Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. Biochim Biophys Acta. 2009;1788:2259–2266.
   PubMed Web of Science ®Google Scholar
• Lehnert BE. Pulmonary and thoracic macrophage subpopulations and clearance of particles from the lung. Environ Health Perspect. 1992;97:17–46.
   PubMed Web of Science ®Google Scholar
• Lin C, Wong BCK, Chen H, et al. Pulmonary delivery of triptolide-loaded liposomes decorated with anti-carbonic anhydrase IX antibody for lung cancer therapy. Sci Rep. 2017;7:1097.
   PubMed Web of Science ®Google Scholar
• Allen TM, Mehra T, Hansen C, et al. Stealth liposomes: an improved sustained release system for 1-beta-D-arabinofuranosylcytosine. Cancer Res. 1992;52:2431–2439.
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46:6387–6392.
   PubMed Web of Science ®Google Scholar
• Golombek SK, May JN, Theek B, et al. Tumor targeting via EPR: strategies to enhance patient responses. Adv Drug Deliv Rev. 2018;130:17–38.
   PubMed Web of Science ®Google Scholar
• Owonikoko TK, Arbiser J, Zelnak A, et al. Current approaches to the treatment of metastatic brain tumours. Nat Rev Clin Oncol. 2014;11:203–222.
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Watanabe R, Choyke PL. Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target? Theranostics. 2014;4:81–89.
   Web of Science ®Google Scholar
• Hansen AE, Petersen AL, Henriksen JR, et al. Positron emission tomography based elucidation of the enhanced permeability and retention effect in dogs with cancer using copper-64 liposomes. ACS Nano. 2015;9:6985–6995.
   PubMed Web of Science ®Google Scholar
• Chauhan VP, Stylianopoulos T, Martin JD, et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nature Nanotech. 2012;7:383–388.
   PubMed Web of Science ®Google Scholar
• Garbuzenko O, Barenholz Y, Priev A. Effect of grafted PEG on liposome size and on compressibility and packing of lipid bilayer. Chem Phys Lipids. 2005;135:117–129.
   PubMed Web of Science ®Google Scholar
• Hadian Z. A review of nanoliposomal delivery system for stabilization of bioactive omega-3 fatty acids. Electron Physician. 2016;8:1776–1785.
   PubMedGoogle Scholar
• Hashizaki K, Taguchi H, Itoh C, et al. Effects of poly(ethylene glycol) (PEG) chain length of PEG-lipid on the permeability of liposomal bilayer membranes. Chem Pharm Bull. 2003;51:815–820.
   PubMed Web of Science ®Google Scholar
• D’Silva JB, Notari RE. Drug stability in liposomal suspensions: hydrolysis of indomethacin, cyclocytidine, and p-nitrophenyl acetate. J Pharm Sci. 1982;71:1394–1398.
   PubMed Web of Science ®Google Scholar
• Verhoef JJ, Anchordoquy TJ. Questioning the use of PEGylation for drug delivery. Drug Deliv Transl Res. 2013;3:499–503.
   PubMed Web of Science ®Google Scholar
• Kelly C, Jefferies C, Cryan SA. Targeted liposomal drug delivery to monocytes and macrophages. J Drug Deliv. 2011;2011:727241.
   PubMedGoogle Scholar
• Oliveira S, Schiffelers RM, van der Veeken J, et al. Downregulation of EGFR by a novel multivalent nanobody-liposome platform. J Control Release. 2010;145:165–175.
   PubMed Web of Science ®Google Scholar
• Klegerman ME, Hamilton AJ, Huang SL, et al. Quantitative immunoblot assay for assessment of liposomal antibody conjugation efficiency. Anal Biochem. 2002;300:46–52.
   PubMed Web of Science ®Google Scholar
• Belfiore L, Spenkelink LM, Ranson M, et al. Quantification of ligand density and stoichiometry on the surface of liposomes using single-molecule fluorescence imaging. J Control Release. 2018;278:80–86.
   PubMed Web of Science ®Google Scholar
• Mack K, Rüger R, Fellermeier S, et al. Dual targeting of tumor cells with bispecific single-chain Fv-immunoliposomes. Antibodies. 2012;1:199–214.
   Google Scholar
• U.S. National Library of Medicine. ClinicalTrials.gov 2019 [cited 2019 June 9]. Available from: https://clinicaltrials.gov/ct2/results?cond=liposomes&term=liposome&cntry=&state=&city=&dist=&Search=Search&recrs=a&recrs=b&recrs=d&recrs=e&recrs=f&phase=4&phase=0&phase=1&phase=2&phase=3
   Google Scholar
• Ozturk-Atar K, Eroglu H, Gursoy RN, et al. Current advances in nanopharmaceuticals. J Nanosci Nanotechnol. 2019;19:3686–3705.
   PubMed Web of Science ®Google Scholar